Nestlé S.A. (NESNN.MX)
| Previous close | 1,762.04 |
| Open | 0.00 |
| Bid | 1,766.72 x 152000 |
| Ask | 1,890.00 x 17300 |
| Day's range | 0.00 - 0.00 |
| 52-week range | |
| Volume | |
| Avg. volume | 434 |
| Market cap | 5.645T |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 13.89 |
| EPS (TTM) | 126.85 |
| Earnings date | 25 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
BenzingaThe Ozempic Diet: Nestle Launches $5 Pizza For Weight Loss Drug Users
On Tuesday, Nestlé SA (OTC:NSRGF) (OTC:NSRGY) unveiled Vital Pursuit, a new line of foods designed to complement GLP-1 weight loss medications and aid consumers focused on weight management. This comes amid fears among investors that food companies could see their sales suffer significantly. Related: Changing Frugal Eating Habits – How Novo Nordisk/Eli Lilly’s Weight Loss Drugs Reshaping Food Spending. The food and drink processing conglomerate says the new line includes protein, fiber, and esse
Barrons.comNestlé and Other Food Makers Cater to Wegovy, Ozempic Users
Weight loss drugs are rising in popularity, and food companies are cooking up new ways to win over those consumers.
FortuneNestlé’s new foods are getting Ozempified, with slashed portions priced specifically for those on weight-loss drugs
The company says its Vital Pursuit line, priced under $5, is high in protein and vitamins, addressing nutrient deficiencies that Ozempic and Wegovy users may have.
